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ABSTRACT 
The Omega-3 Fatty Acid Content of Krill Protein Concentrate Influences 
Bioavailability, Tissue Deposition, Peroxidation, and Metabolism in Young Rats    
 
Kayla Marie Bridges 
 
Objective: Krill protein concentrate (KPC) has been determined to be a high quality 
protein for human consumption with the advantage of being a rich source of the omega-3 
polyunsaturated fatty acids (ω-3 PUFAs), docosahexaenoic acid (DHA) and 
eicosapentaenoic acid (EPA).  The ω-3 PUFAs in krill are mainly associated with 
phospholipids, which have been proposed to result in high incorporation of ω-3 PUFAs 
into tissues and to be stable against oxidation.  The study objective was to determine 
bioavailability, tissue deposition, peroxidation, and metabolism of ω-3 PUFAs in rats fed 
KPC.   
Methods: Young female Sprague-Dawley rats (n=10/group) were fed ad libitum 
isocaloric diets with either 10% freeze-dried KPC containing 0.9% krill oil with 4.4% 
corn oil (KO + CO) or 10% casein with 5.3% corn oil (C+CO) for 4 weeks.  
Bioavailability was measured by determining apparent digestibility of dietary lipid during 
the final week of the study.  Fatty acid compositions of diets, various tissues, and feces 
were analyzed by gas chromatography.  Lipid peroxidation was determined by TBARS. 
Total antioxidant capacity and urinary eicosanoid metabolites were determined by 
enzyme immunoassay.   
Results: Rats fed KO + CO had a low apparent digestibility (%) of AA (22.75±6.45), 
moderate apparent digestibility (%) of EPA (70.12±3.52) and high apparent digestibility 
(%) of DHA (93.42±1.64).  The 0.9% KO from KPC increased (P<0.01) EPA and DHA 
content in adipose and liver tissue while decreasing (P<0.01) the ω-6 PUFA, arachidonic 
acid.  DHA was increased (P=0.003) in the brain of rats fed KO + CO.  There was no 
significant difference in total antioxidant capacity or lipid peroxidation between diets.   
Feeding the KO + CO diet decreased (P=0.009) urinary PGE2 metabolites. There was a 
tendency (P=0.054) for decreased urinary 11-dehydro TXB2 in rats fed KO + CO. 
Conclusion: The 0.9% KO from KPC provided by the diet was able to increase ω-3 
PUFAs and decrease AA tissue accretion resulting in reduced pro-inflammatory 
eicosanoid metabolites.  The results suggest that KPC from krill provides a healthy and 
sustainable alternative to fish or fish oil supplement. 
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1.0 Introduction 
The beneficial effects of fish have been attributed to the omega-3 polyunsaturated 
fatty acids (ω-3 PUFAs) content, docosahexaenoic acid (DHA, 20:6 ω-3) and 
eicosapentaenoic acid (EPA, 20:5 ω-3).  However, other components than ω-3 PUFAs 
may be health beneficial.  Feeding protein derived from fish to laboratory animals have 
been shown to reduce the plasma cholesterol level compared to casein (Jacques et al., 
1995).  Recently, Wergedahl et al. (2009) reported that the dietary combination of fish 
protein and lipid may be synergistic.  Therefore, consuming fish rather than fish oil 
supplements may provide optimal health benefits.  However, depletion of existing fish 
stocks and environmental contaminants raises public concern regarding fish consumption.   
A potential alternative to fish consumption is to promote consumption of 
underutilized species such as krill. Krill is a marine crustacean having the largest animal 
biomass on Earth (Nicol et al., 1987), yet it has remained virtually untapped as a food 
source.  Additionally, krill has been reported to contain lower mercury levels compared 
to most fish (Nicol et al., 1987).  Previously, the lack of an effective technology for meat 
recovery from krill has hindered its commercial development. 
Nutritional evaluation of krill protein concentrate (KPC) indicated it to be a 
source of high quality protein with the advantage of being a rich source of the ω-3 
PUFAs, DHA and EPA (Gigliotti et al., 2008).  The ω-3 PUFAs associated with krill are 
predominantly in phospholipid (PL) form, whereas ω-3 PUFAs in most marine sources 
are in the form of triacylglycerides (TAG) (Bottino, 1975).  Since PLs are digested 
differently than TAGs, the bioavailability of ω-3 PUFAs from krill may differ.  Amate et 
al. (2001) observed that rats fed PUFAs as egg PLs had lower fecal excretion of DHA 
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and higher feed efficiency ratios than rats fed PUFAs in the TAG form, indicating better 
apparent absorption.  In turn, this may affect how efficiently EPA and DHA are 
incorporated into tissues.  
Valenzuela et al. (2005) reported that feeding female rats DHA supplemented in 
the form of egg phospholipids resulted in higher accretion of DHA in liver and adipose 
tissue compared to supplementation in the form of TAGs.  In contrast, Song et al. (2001) 
found that rats fed DHA in PL form had lower incorporation of DHA in liver than rats 
fed DHA in the form of TAGs.  Studies regarding tissue incorporation of ω-3 PUFAs 
from KPC are important because EPA and DHA exert anti-inflammatory properties.  
Inflammation has been reported to play a role in various diseases states (Calder 2006).    
EPA and DHA compete with AA for the sn-2 position of phospholipids of cell 
membranes, affecting the availability of AA in tissues for cleavage by phospholipase A2 
and use in eicosanoid production.  EPA also competes as a substrate for COX-2 which 
results in reduction of pro-inflammatory 2-series prostanoids and thromboxanes (Calder 
2006). 
On the other hand, EPA and DHA are highly susceptible to lipid peroxidation due 
to their high degree of unsaturation.  Song et al. (2001) demonstrated that increased levels 
of DHA in membrane phospholipids increased Thiobarbituric Acid Reactive Substances 
(TBARS); however, when provided in PL form did not increase lipid peroxidation.  This 
is important because a source of ω-3 PUFAs that could provide high tissue accretion with 
the least lipid oxidation would favor maximal health benefits.  Therefore, the objective of 
this study was to investigate the bioavailability and effects of ω-3 PUFAs from KPC on 
tissue deposition, peroxidation, and lipid metabolism. 
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2.0 Literature Review 
2.1 Overview of ω-3 PUFAs 
The three most biologically active ω-3 PUFAs are α-linolenic acid (ALA, 
18:2 ω-3), EPA, and DHA.  The human body cannot synthesize ALA, making it 
essential.  The essential long-chain PUFAs are important because they are 
precursors of short-lived eicosanoids, which are signaling molecules involved in 
the inflammatory response.  EPA and DHA can be synthesized from ALA if it is 
provided in the diet.  EPA and DHA play a number of important biological roles.  
However, metabolic conversion of ALA to EPA and DHA is inefficient in 
humans and varies in other species (Arterburn et al., 2006).  EPA and DHA are 
mainly obtained from marine sources with fish being the most common dietary 
source.  Approximately 19% of total fatty acids in Antarctic krill are ω-3 PUFAs, 
with EPA and DHA being particularly abundant (Kolakowska et al., 1994).  Total 
lipids in Antarctic krill contain 15 to 21% EPA and 9 to 14% DHA (Phleger et al., 
2002).  Therefore, acceptance of krill for human consumption has the potential to 
provide another rich food source of EPA and DHA. 
2.2 Bioavailability of Different Forms of ω-3 PUFAs 
The ω-3 PUFAs in fish are mostly found in the form of TAG, whereas the 
ω-3 PUFAs in krill are mainly associated with phospholipids.  According to 
Bottino (1975), about 58% of total lipids in krill are in the PL form.  Dietary PLs 
have been suggested to have better absorption compared to TAG due to their 
ability to interact with water in the gut; this may enhance luminal lipid 
solubilization.  Nishioka et al. (2004) demonstrated that administration of 
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phosphatidylcholine enhanced lipid absorption in bile-deficient rats.  The 
difference in the position of the fatty acids associated with either PLs or TAG 
may affect absorption as well.  EPA and DHA are typically found at the sn-2 
position of PLs and TAGs.  In the TAG form, the fatty acids in the sn-1 and sn-3 
positions of TAG are cleaved by pancreatic lipase to free fatty acids and the ω-3 
PUFA is absorbed as a 2-monoacylglycerol.  In the PL form, the EPA or DHA in 
the sn-2 position is cleaved upon absorption.  The ω-3 PUFA is absorbed as a free 
fatty acid and can be re-esterfied to TAG or 1-lysolechitin in the enterocyte. In the 
enterocyte, the digestion products of the dietary fats are incorporated into 
chylomicrons, which are secreted into the lymph then the bloodstream for 
distribution in the body.  Since the ω-3 PUFAs associated with PLs are digested 
differently than those associated with TAGs, the bioavailability of ω-3 PUFAs in 
the PL form may differ from ω-3 PUFAs in the TAG form. 
Amate et al. (2001) observed that rats fed PUFAs as egg PLs had lower 
fecal excretion of DHA and higher feed efficiency ratios than rats fed PUFAs in 
the TAG form, indicating better apparent absorption.  However, studies are 
needed to determine the bioavailability of ω-3 PUFAs from krill. 
2.3 Tissue Incorporation of ω-3 PUFAs 
The ω-3 PUFAs are widely distributed in the body as part of the cell 
membrane phospholipids (Arterburn et al., 2006).  Incorporation of ω-3 PUFAs 
into liver tissue is especially important since the liver is the main site of fatty acid 
and lipoprotein metabolism.  Amate et al. (2001) compared the distribution of 
fatty acids in plasma lipoproteins in piglets fed either a control diet, a diet 
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containing PUFAs as TAG from tuna and fungal oils, or a diet containing PUFAs 
as egg PLs.  These diets contained 0.6 g/100g arachidonic acid (AA, 20:4 ω-6) 
and 0.3g/100g DHA.  The authors found that feeding PUFAs as egg PLs resulted 
in a higher incorporation of dietary AA and DHA into HDL phospholipids. 
DHA is particularly abundant in brain and retina tissue and plays an 
important role in the maintenance of normal neural function (Arterburn et al., 
2006; Horrocks et al., 1999).  The ω-3 PUFAs that are not incorporated into cell 
membranes or oxidized for energy are stored in adipose tissue as TAGs.  Current 
dietary recommendations refer to a combined amount of EPA and DHA.  Kris-
Etherton et al. (2002) defined typical recommendations for EPA+DHA as 0.3 to 
0.5 g/day.  However, tissue EPA and DHA may not exactly reflect dietary 
amounts of EPA and DHA because tissue incorporation is affected by total fatty 
acid content of the diet. 
2.4 Factors Affecting Tissue Incorporation of the ω-3 PUFAs 
Dietary concentration of linoleic acid (LA, 18:2 ω-6) and ALA should be 
considered when evaluating tissue composition of EPA and DHA. Concentrations 
of LA and ALA affect endogenous synthesis of either long-chain ω-6 PUFAs or 
ω-3 PUFAs, respectively, due to competitive substrate/product inhibition. 
Endogenous synthesis of EPA and DHA from ALA utilizes the enzyme Δ-6 
desaturase (Figure 1).  However, this enzyme also catalyzes the first step in 
synthesis of the long-chain ω-6 PUFA, AA, from LA.  The high affinity of ALA 
for Δ-6 desaturase may decrease synthesis of AA from LA (Benatti et al., 2004). 
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Figure 1.  PUFA Metabolism 
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Supplementation of DHA has also been shown to decrease metabolites of 
LA and ALA in plasma lipid profiles (Emken et al., 1999).  AA is the biological 
precursor for pro-inflammatory eicosanoids; therefore, too much AA in tissues 
could increase risk of cardiovascular disease (CVD) and other inflammatory 
diseases.  AA competes with EPA and DHA for the sn-2 position in phospholipids 
of cell membranes (Figure 1).  It has been shown that supplementation of EPA 
and DHA with no AA increases tissue incorporation of EPA and DHA while 
decreasing AA (Innis et al., 1995).  Dietary EPA and DHA supplementation may 
then decrease endogenous synthesis of the pro-inflammatory ω-6 PUFA, AA, 
from the 18 carbon precursors, LA, while providing the less inflammatory long-
chain ω-3 PUFAs, resulting in decreased CVD risk.  Similarly, high concentration 
of the long-chain ω-6 AA affects tissue incorporation of the long-chain ω-3 
PUFAs, EPA and DHA. 
Dietary source may also affect how efficiently EPA and DHA are 
incorporated into tissues.  Valenzuela et al. (2005) compared the effects of 
different DHA sources on tissue accretion in female rats.  DHA supplementation 
in the form of egg PLs resulted in higher accretion of DHA in liver and adipose 
tissue compared to supplementation in the form of TAGs or ethyl esters.  
According to these results, DHA associated with PLs is more efficiently 
incorporated into tissues.  However, Song et al. (2001) found that rats fed DHA in 
PL form had lower incorporation of DHA in liver and plasma phospholipids than 
rats fed DHA in the form of TAGs or ethyl esters.  Clearly, more studies are 
needed to confirm the effect of different dietary sources of ω-3 PUFAs on tissue 
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incorporation because they contribute to membrane fluidity and serve as 
precursors for less inflammatory eicosanoids. 
Tissue incorporation of EPA and DHA may also differ from dietary 
content due to interconversion between EPA and DHA in the body.   Innis et al. 
(1995) performed a study comparing the effect of marine versus freshwater fish 
oil on fatty acid incorporation into the tissues of growing rats.  The marine oil diet 
contained similar DHA as the freshwater fish oil diet, but lower AA and higher 
EPA.  The results showed that despite having a similar DHA content as the 
freshwater fish oil diet, the marine oil diet had higher liver, brain, kidney, and 
heart tissue accretion of DHA.  The authors attributed these results to a high 
conversion rate of EPA to DHA in the marine oil diet.  Murphy et al. (1997) 
found that guinea pigs fed a diet with higher EPA than DHA had higher heart 
tissue accretion of DHA compared to EPA.  These authors also suggested that this 
was due to a high conversion of EPA to DHA.  However, these diets contained 
neither the EPA or DHA precursor, ALA, or the ω-6 PUFA, AA, and minimal 
amounts of LA. 
Based on these study results, levels of the other ω-3 and ω-6 PUFAs must 
be taken into consideration when evaluating tissue incorporation of EPA and 
DHA from KPC.  The lipid component of KPC contains relatively equal amounts 
of EPA and DHA (~12% total fatty acids each) while providing a minimal amount 
of AA (~1.2% total fatty acids) (Gigliotti et al., 2008).  It also contains small 
amounts of the PUFA ω-3 precursor, ALA (~1.5% total fatty acids), and the ω-6 
PUFA precursor, LA (~3.1% total fatty acids) (Gigliotti et al., 2008).  To our 
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knowledge, no studies have examined tissue incorporation of EPA and DHA in 
response to KPC supplementation. 
2.5 Oxidative Stability of ω-3 PUFAs 
Increased tissue amounts of ω-3 PUFAs have been shown to produce a 
number of health benefits.  However, the ω-3 PUFAs are also highly susceptible 
to oxidation due to their high degree of unsaturation.  Auto-oxidation of PUFA in 
membrane phospholipids generates a mixture of epoxides, hydroperoxides, and 
cyclic peroxides (Porter et al., 1995).  DHA is particularly susceptible to 
peroxidation because it contains 6 double bonds.  Saito et al. (2002) found that 
feeding rats 8.4% total energy as purified DHA for 30 days significantly increased 
lipid peroxidation as evidenced by increased thiobarbituric acid reactive 
substances (TBARS). 
Song et al. (2001) demonstrated that increased levels of DHA in 
membrane phospholipids increased TBARS in rats fed DHA as either TAG or 
ethyl esters.  The authors also found that there was a greater loss of ω-3 PUFAs 
than ω-6 PUFAs as a result of lipid peroxidation, indicating that ω-3 PUFAs are 
more susceptible to lipid peroxidation than ω-6 PUFAs.  Interestingly, Song et al. 
(2001) found that DHA provided in PL form did not increase lipid peroxidation.  
These results suggested that ω-3 PUFAs provided as PLs may have higher 
stability against peroxidation than DHA provided as TAG or ethyl esters.  This is 
important because a source of ω-3 PUFAs that could provide high tissue accretion 
with the least lipid oxidation would favor maximal health benefits.  Krill oil is 
high in PLs and since the ω-3 PUFAs associated with PLs may be more stable 
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against lipid peroxidation than tissue associated with TAG, it is important to 
evaluate the effect of ω-3 PUFAs from KPC on oxidative stability. 
Large amounts of lipid auto-oxidation products contribute to atherogenesis 
(Porter et al., 1995).  Leigh-Firbank et al. (2002) found that supplementation of 
EPA + DHA increased LDL-cholesterol and oxidation of LDL.  Oxidized LDL 
plays a central role in the initiation as well as the progression of the atherogenic 
process (Gropper et al., 2005).  These studies suggested that increased levels of ω-
3 PUFAs induce lipid peroxidation and may contribute to atherosclerosis. 
Endogenous antioxidants function to defend against unstable free radicals 
such as reactive oxygen species that cause damage to lipids, protein, and DNA 
(Halliwell, 1996).  However, increased lipid peroxides may exhaust the body’s 
antioxidant defense system.  Disturbance in the balance between reactive oxygen 
species such as lipid peroxides and antioxidants results in oxidative stress.  
Oxidative stress increases the risk of inflammatory diseases such as CVD.  
Therefore, it is also critical to determine the effect of ω-3 PUFAs from KPC on 
tissue oxidation and the body’s antioxidant defense system. 
2.6 Effect of ω-3 PUFAs on Cardiovascular Health 
The prevalence of CVD among Americans has led to increased importance 
of dietary intervention and prevention.  The ω-3 PUFAs have received much 
attention due to reports of anti-inflammatory properties and improvement of the 
plasma lipids and lipoprotein profile.  EPA and DHA have been shown to produce 
hypotriglyceridemic effects (Grimsgaard et al., 1997).  In vitro studies have 
suggested that EPA may be more effective in lowering serum TAG than DHA 
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(Leigh Firbank et al., 2002; Rambjor et al., 1996; Wong et al., 1989).  However, 
other studies have found that EPA and DHA exert similar hypotriglyceridemic 
effects (Woodman et al., 2002; Grimsgaard et al., 1997).   
EPA and DHA have been found to decrease plasma cholesterol (Froyland 
et al., 1996).  DHA has been found to reduce HMG-CoA reductase activity, which 
could contribute to a hypocholesterolemic effect (Froyland et al., 1996).  EPA and 
DHA have also been shown to affect plasma lipoproteins.  Studies evaluating the 
effects of EPA and DHA on plasma lipoproteins are inconclusive.  DHA has been 
suggested to increase LDL-cholesterol (Leigh-Firbank et al., 2002; Mori et al., 
2000).  Rambjor et al. (1996) attributed increased LDL-cholesterol to EPA.  
Bunea et al. (2004) compared the effects of providing subjects with supplement of 
fish oil or krill oil on serum lipid and lipoprotein profiles.  According to this 
study, daily supplementation of 1 to 1.5 grams of krill oil for 90 days resulted in a 
greater (P<0.001) decrease in serum cholesterol and increased HDL compared to 
subjects who received 3 grams of fish oil per day.  Other studies have shown that 
DHA decreased HDL-cholesterol (Saito et al., 2002).  Gigliotti et al. (2008) found 
that KPC decreased (P=0.004) HDL-cholesterol in rats. 
The cardioprotection provided by EPA and DHA may not be 
predominantly due to the effects on plasma lipoproteins. Antithrombotic effects of 
fish oil have been attributed to decreases in platelet aggregation, thromboxane A2 
(TXA2), and blood viscosity (Benatti et al., 2004).  Park et al. (2002) found that 
EPA decreased mean platelet volume, an early step in platelet aggregation.  
Engstrom et al. (1996) found that administration of 30 g/d of fish oil containing 
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17% EPA and 11.7% DHA decreased the stable TXA2 metabolite, thromboxane 
B2 (TXB2), in men.  DHA has been shown to have hypotensive effects and 
decrease cardiac arrhythmias (Benatti et al., 2004; Horrocks et al., 1999).   Both 
EPA and DHA interfere with the production of inflammatory eicosanoids from 
AA through the cyclooxygenase (COX) pathway. EPA competes as a substrate for 
COX-2 and results in the production of less inflammatory 3-series prostanoids 
and 5-series leukotrienes.  Dusing et al. (1997) demonstrated this using 
administration of 3.6 g/d EPA and 2.4 g/d DHA in humans; this significantly 
decreased urinary excretion of prostaglandin E2 (PGE2) while increasing 
prostaglandin E3. 
EPA and DHA incorporated into the tissues may differ depending on the 
source.  Thus, the beneficial effects of ω-3 PUFAs may depend more on tissue 
composition than diet composition.  Therefore, it is important to determine the 
bioavailability, tissue deposition, oxidative stability, and lipid metabolism of EPA 
and DHA from dietary KPC. 
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3.0 Study Objectives 
 
Objective 1.  To determine the bioavailability and tissue deposition of ω-3 
PUFAs from dietary KPC. 
 
Objective 2.  To determine the effects of ω-3 PUFAs from dietary KPC on 
oxidative stress. 
 
Objective 3.  To determine the effects of f ω-3 PUFAs from dietary KPC on lipid 
metabolism. 
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4.0 Materials and Methods 
4.1 Diets 
Whole frozen Antarctic krill (Euphausia superba) were purchased from 
Krill Canada (Langley, BC, Canada).  KPC was recovered from whole krill using 
an isoelectric solubilization/precipitation method (Chen & Jaczynski, 2007).  The 
proximate composition of recovered KPC after freeze-drying was 77.7% crude 
protein, 8.1% total lipid, and 4.4% total ash (Gigliotti et al., 2008).  Diets were 
based on a standard purified AIN-93G diet (Reeves et al., 1993).  Modifications 
of the AIN-93G diet consisted of replacing soybean oil with corn oil and 10% 
crude protein supplied as KPC or casein (Table 1).  Replacement of the protein as 
either KPC or casein was corrected for protein and lipids so that the diets were 
isocaloric and isonitrogenous.  Both diets contained 5.3% total lipid.  The casein 
diet contained 5.3% corn oil (CO) whereas the KPC contained 0.9% krill oil from 
KPC and 4.4% corn oil (KO + CO).  Fatty acid analysis of the diets is shown in 
Table 2.  Diets containing KPC were prepared weekly and kept stored at 4°C.  
4.2 Animal Feeding Study 
All animal procedures were approved by the Animal Care and Use 
Committee at West Virginia University and were conducted in accordance with 
the guidelines set forth by the Institute of Laboratory Animal Resources 
Commission on Life Sciences for the Care and Use of Laboratory Animals 
(1996).  Young (28 d) female Sprague-Dawley rats were purchased from Taconic 
Farms (Rockville, MD).  Upon arrival at the animal care facility, rats were 
individually housed in metabolic cages to determine food intake and to collect 
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urine and feces.  Rats were kept caged in rooms maintained at 21oC with a 12 h 
light/dark cycle.  During a 14 d acclimation period, animals were given ad libitum 
access to deionized distilled water (ddH2O) and AIN-93G diet (Harklan Teklad; 
Indianapolis, IN).  Following the 14 d acclimation period, rats (n=10/group) were 
randomly assigned to be fed ad libitum either 10% casein with 5.3% CO or KPC 
with 0.9% KO and 4.4% CO (KO + CO).  Food intake was measured biweekly.  
At the end of the 4 weeks, rats were euthanized by CO2 inhalation.  
Retroperitoneal and gonadal fat pads, brain, and liver were dissected and weighed.   
There were no significant differences in food intake (Gigliotti et al., 2008).  
There were no significant differences in final body weights between rats fed KPC 
diet with KO + CO compared to rats fed casein diet with CO (Gigliotti et al., 
2008).  Rats fed KO + CO had higher retroperitoneal (P=0.02) and gonadal 
(P=0.03) fat pad weights than rats fed CO (Gigliotti et al., 2008).  There were no 
significant differences in brain or liver weights between KO + CO and C+CO fed 
rats (Gigliotti et al., 2008). 
4.3 Bioavailability 
Bioavailability was measured by determining apparent digestibility of 
dietary lipid during the final week of the study.  Fecal samples were freeze-dried 
for 48 h.  Total fecal lipid was determined by Soxhlet extraction.  Apparent 
digestibility (%) was determined using the formula [(lipid intake-fecal lipid)/(lipid 
intake)] x 100 (Deuchi et al., 1994).  Similarly, apparent digestibility (%) of 
individual fatty acids were determined using the formula [(fatty acid intake-fecal 
fatty acids)/(fatty acid intake)] x 100. 
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4.4 Fatty Acid Analysis 
Lipids were extracted from the gonadal and retroperitoneal fat pads, liver, 
brain, and feces according to the method by Bligh and Dyer (1959).   All tissue 
samples were conducted in duplicates.  Tissues were weighed and 48 μL of 
heptadecenoic acid (17:1) was added as an internal standard.  Weighed samples 
were added to Tris/EDTA buffer pH 7.4.  A chloroform:methanol:acetic acid 
(2:1:0.15 v/v/v) solution was added to the samples.   Samples were centrifuged at 
900 x g for 10 minutes at 10oC and the bottom chloroform layer was collected. 
The collected chloroform was then filtered through 1-phase separation filters to 
remove any remaining water and precipitated material. The remaining layer was 
then mixed with chloroform:methanol (4:1 v/v) and centrifuged at 900 x g for 10 
min at 10oC.  The chloroform layer was collected and filtered.  The extracted lipid 
was dried under nitrogen gas.   
The extracted lipid samples were transmethylated following the procedure 
described by Fritsche and Johnston (1990). Extracted fatty acids were methylated 
by adding 4% H2SO4 in anhydrous methanol to the dried lipid samples followed 
by incubation in a 90oC water bath for 60 minutes. Samples were cooled to room 
temperature and 3 mL of deionized distilled H2O was added to stop the reaction.  
Chloroform was added to the methylated sample.  Samples were again dried 
under nitrogen gas, and iso-octane (3 mL) was used as a diluent. 
The methylated lipid samples were analyzed by gas chromatography (CP-
3800, Varian Inc., Walnut Creek, CA) using an initial temperature of 140oC held 
for 5 minutes and then increased 1oC per min to a final temperature of 220oC.  A 
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wall-coated open tubular (WCOT) fused silica capillary column (Varian Inc., 
Walnut Creek, CA) was used to separate fatty acid methyl esters (FAME) with 
CP-Sil 88 (Varian Inc., Walnut Creek, CA) as the stationary phase. Nitrogen was 
used as the carrier gas, and total separation time was 110 minutes. Quantitative 37 
Component FAME Sigma Mix (Supelco, Bellefonte, PA) was used to identify 
fatty acid composition.  Fatty acids were identified using retention time and peak 
area counts with Star GC Workstation computer software (Varian Inc., Walnut 
Creek, CA). 
4.5 Thiobarbituric Acid Reactive Substances (TBARS) 
TBARS were measured using a commercially available enzyme 
immunoassay (EIA) kit (Cayman Chemical, Ann Arbor, MI).  Urine collected at 
baseline and on the final week (week 4) of the feeding study was used to measure 
lipid peroxidation.  Homogenates of gonadal and retroperitoneal fat pads, liver, 
and brain were used to measure lipid peroxidation in these tissues.  Samples were 
mixed with sodium dodecyl sulfate (SDS) solution and a color reagent containing 
thiobarbituric acid (TBA), acetic acid, and sodium hydroxide.  Samples were 
incubated for 60 minutes in a 90 oC water bath and then incubated in an ice bath 
for 10 minutes to stop the reaction.  Following centrifugation for 10 minutes at 
1,600 x g at 4 oC, samples were measured colorimetrically.  Absorbance was read 
at 540 nm using a Spectramax Plus microplate reader (Molecular Devices, CA) 
and values were expressed as µM MDA (malondialdehyde). 
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4.6 Total Antioxidant Capacity 
Total antioxidant capacity was measured according to a commercially 
available EIA Antioxidant Assay kit (Cayman Chemical, Ann Arbor, MI).  Urine 
collected from the baseline and final weeks was diluted with 5 mM potassium 
phosphate buffer containing 0.9% sodium chloride and 0.1% glucose at pH 7.4 
(1:20 v/v).  Trolox (6-Hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid), a 
water soluble tocopherol analogue, was added to standard wells, and sample 
diluted to 1:20 were added in duplicates to wells. Metmyoglobin and ABTS (2,2’-
Azino-di-[3-ethylbenzthiazoline sulphonate]) were then added to all wells.  To 
initiate the reaction, hydrogen peroxide was added to each well.  Samples were 
then incubated at room temperature on a shaker for 5 minutes.  Absorbance was 
read at 750 nm using a Spectramax Plus microplate reader (Molecular Devices, 
CA).  Antioxidant concentration was expressed as mM Trolox. 
4.7 Eicosanoid Measurements 
The effect of ω-3 PUFAs from KPC on lipid metabolism was determined 
by measuring urinary eicosanoids.  Efficacy in reducing the inflammatory AA 
product, PGE2, was measured in urine using to Cayman’s Prostaglandin E 
Metabolite Enzyme Immunoassay (Cayman Chemical, Ann Arbor, MI).   
Effect on reducing thrombosis was determined by measuring pro-
thrombotic AA thromboxanes.  TXA2 is short-lived, therefore a stable metabolite 
11-dehydro TXB2 was measured in the urine using commercial enzyme 
immunoassay kit (EIA, Cayman Chemical, Ann Arbor, MI).   
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4.8 Statistical Analysis 
The Student’s t-test was used to compare differences between treatment 
groups, and Mann-Whitney Rank Sum test was performed on data not normally 
distributed.  Differences were considered significant at P<0.05.  Results are 
expressed as mean ± SEM.  Results were analyzed using SigmaStat 3.1 statistical 
software program (Systat Software Inc., San Jose, CA). 
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5.0 Results 
5.1 Lipid and Fatty Acid Bioavailability 
No significant difference was found in total lipid intake, total lipid content 
of feces, or apparent digestibility (%) of dietary total lipid between groups (Table 
3).  Rats fed KO + CO had a lower (P=0.001) intake of LA and higher (P<0.05) 
intake of ALA, AA, EPA, and DHA.  There were no differences in fecal excretion 
of LA or ALA by rats fed KO + CO compared to rats fed CO.  Apparent 
digestibility (%) of the AA precursor, LA, was significantly decreased (P=0.02) in 
rats fed KO + CO compared to rats fed CO, while apparent digestibility (%) of the 
long-chain ω-3 PUFA precursor, ALA, was unaffected.  Rats fed KO + CO had a 
low apparent digestibility (%) of AA (22.75±6.45), moderate apparent 
digestibility (%) of EPA (70.12±3.52) and high apparent digestibility (%) of DHA 
(93.42±1.64).   
5.2 Fatty Acid Analysis of Tissues 
To investigate the effect of KO + CO on tissue fatty acid deposition, 
analysis was performed on retroperitoneal and gonadal fat pads, liver, and brain 
(Table 4).  There were no significant differences in LA or ALA tissue content 
between groups.  Deposition of AA was decreased in rats fed KO + CO in 
retroperitoneal fat pad (P=0.002) and liver tissue (P<0.001).  Rats fed KO + CO 
also displayed a tendency (P=0.056) for lower AA gonadal fat pad deposition. No 
difference in AA brain deposition was found between groups. 
Rats fed KO + CO had significantly higher tissue deposition of EPA in 
retroperitoneal and gonadal fat pads (P=0.004) and liver (P<0.001) compared to 
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rats fed CO only.  EPA was not present in detectable amounts in brain tissue of 
either group.   Tissue deposition of DHA was significantly increased in rats fed 
KO + CO in retroperitoneal (P=0.003) and gonadal (P=0.021) fat pads, liver 
(P<0.001), and brain (P=0.003) compared to rats fed CO only. 
5.3 Oxidative Stability 
To determine the effect of ω-3 PUFAs provided by KPC on lipid 
oxidation, TBARS were measured in various tissues (Table 5).  There were no 
significant differences in retroperitoneal fat pad, liver, or brain TBARS between 
the groups.  Rats fed KO + CO had significantly decreased (P=0.032) TBARS in 
the gonadal fat pad compared to rats fed CO only.  No significant difference was 
found in baseline and final TBAR concentrations in urinary samples between 
groups.  However, rats fed KO + CO displayed a trend (P=0.06) toward lower 
final urinary TBARS. 
Total antioxidant capacity was measured to determine whether the ω-3 
PUFAs provided by KPC had an effect on endogenous antioxidant function 
(Table 5).  There were no differences between groups or between baseline and 
final urinary total antioxidant capacity. 
5.4 Eicosanoid Measurements 
Urinary metabolites of the pro-inflammatory AA product, PGE2, were 
reduced (P=0.009) in rats fed KO + CO compared to rats fed CO only (Figure 2).  
There was a tendency (P=0.054) for reduced TXA2 metabolite, 11-dehydro TXB2, 
in rats fed KO + CO (Figure 3). 
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6.0 Discussion & Conclusion 
 6.1 Discussion 
KPC provides a high quality protein and a rich source of the ω-3 long-
chain PUFAs (LCPUFAs), EPA and DHA.  KPC consisting of 0.9% KO blended 
with CO, which contains negligible amounts of AA, EPA, and DHA, resulted in 
measurable concentrations.  Most studies reporting increased EPA and DHA 
tissue deposition have used large doses of pure oil (Arterburn et al., 2006).  Low 
doses and mixtures of oil are more representative of the human diet.  AA, EPA, 
and DHA can also be synthesized in the body from the essential fatty acids.  
Sufficient dietary ALA intake promotes EPA and DHA synthesis, and LA 
promotes AA synthesis.  ALA content was slightly higher and LA content lower 
in KO + CO compared to CO alone.  Whether altered dietary fatty acid affects 
incorporation into tissues and conversion to other fatty acids will depend on the 
bioavailability of the fatty acid. 
Bioavailability of EPA and DHA precursor, ALA, was low for both oils.  
Apparent digestibility of ALA was lower in rats fed KO + CO (49%) compared to 
CO (63%).  However, KO + CO provided DHA with high apparent digestibility 
(93%) and EPA with moderate apparent digestibility (70%).  Although CO 
contains negligible AA, bioavailability of the AA precursor, LA, was high.  Rats 
fed KO + CO had significantly lower apparent LA digestibility (93%) compared 
to rats fed CO (96%).  This was due to lower (P=0.001) intake of LA in the KO + 
CO diet and absences of difference in fecal excretion between the groups.  Also,  
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the AA provided by KO + CO showed low apparent digestibility (23%).  
Differences in fatty acid bioavailability may be due to fatty acids in KO being 
associated with PLs and CO with TAGs. 
Animal and human studies have indicated that DHA and AA are important 
to the development of the central nervous system (Innis, 2007).   AA and DHA 
were detectable in the brains of rats fed CO despite negligible amounts in the diet. 
Thus, it is likely that conversion of LA and ALA by the desaturation-elongation 
pathway occurred in neural tissue.  However, studies have suggested that 
conversion of essential fatty acids to the LC PUFAs may not be sufficient to 
support the needs of growing infants.  To ensure adequate intake, infant formulas 
are often supplemented with DHA in the form of TAGs or egg PLs.  In our study, 
growing rats fed KO + CO had higher (P=0.003) DHA deposition in brain tissue 
compared to rat fed CO.  Clinical trials with premature infants reported that DHA 
provided as egg PL resulted in better absorption than DHA provided as TAGs 
(Carnielli et al., 1998). 
Innis et al. (1995) reported that feeding rats a diet composed of a 2% 
safflower oil and 10% marine fish oil blend (0.9% AA; 15.1% EPA; 7.3% DHA) 
for 4 weeks increased brain EPA and DHA and decreased AA compared to rats 
fed 12% safflower oil.  In our study, the 0.9% KO from KPC provided 1.5% AA, 
12.5% EPA, and 12.7% DHA for 4 weeks, but did not lead to detectable brain 
EPA.  According to Arterburn et al. (2006), EPA is typically found in low to non-
detectable amounts in brain tissue.  Additionally, feeding rats KO + CO for 4 
weeks increased DHA without decreasing AA brain content.  This is important 
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because DHA in conjunction with AA is considered necessary to support proper 
growth and development during the early and rapid growth phase of life 
(Mathews et al., 2002). 
The nervous system is the organ with the second largest PUFA 
concentration of lipids, only exceeded by adipose tissue (Benatii et al., 2004).  
Dietary fatty acids not used for incorporation into cell membrane phospholipids, 
oxidation, or other metabolic purposes are stored in adipose tissue as TAG.  In 
human adipose tissue, LA is the most abundant PUFA at ~12-16% of fatty acids 
and ALA is the most abundant ω-3 PUFA at ~1% (Arterburn et al., 2006).  In our 
animal study, LA and ALA content of fat pads were similar in rats fed both diets.  
EPA and DHA were increased in fat pads of rats fed KO + CO; whereas, neither 
of these long-chain ω-3 PUFAs were detectable in rats fed CO.  Therefore, 
adipose tissue reflected the dietary intake of fatty acids.  Detectable AA content in 
the fat pads of rats fed AA-deficient CO diet indicated conversion from LA.  
Lower AA deposition in the fat pads of KO + CO compared to CO fed rats may 
have resulted from poor bioavailability of AA in the PL form. 
The liver is the main site of fatty acid synthesis and conversion (Arterburn 
et al., 2006).  ALA was not detectable in liver tissue of rats fed either diet; this 
may be due to low apparent digestibility of the ALA in both diets and conversion 
to DHA.  This is indicated by measureable DHA content in the liver tissue of rats 
fed the DHA-deficient CO diet.  Werner et al. (2004) found that feeding ALA in 
the PL form increased DHA content in the liver compared to the TAG form; the 
authors attributed this to greater bioavailability.  However, this study was 
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conducted in essential fatty acid deficient mice; whereas, the rats in our study 
were provided sufficient efficient fatty acids.  Froyland et al. (1996) reported 
minimal amounts of ALA in liver phospholipids of Wistar rats and these amounts 
did not differ with supplementation of EPA, DHA, or CO for three months.  
Therefore, the higher liver EPA and DHA content in the rats fed KO + CO was 
due to KO providing a dietary source of EPA and DHA. 
Measureable AA in the liver tissue of rats fed the AA-deficient CO diet 
suggests conversion from LA.  Rats fed KO + CO diet had reduced AA deposition 
in the liver compared to rats fed CO despite AA being provided in the diet.   
Tissue AA content is affected by EPA and DHA due to competition for the sn-2 
position of phospholipids in cell membranes (Gropper et al., 2005).  Therefore, 
reduced liver AA in rats fed KO + CO compared to CO may be due to the poor 
bioavailability of AA as well as competitive inhibition with EPA and DHA. 
Froyland et al. (1996) found that feeding male rats a diet with either 94% 
of total fatty acids as EPA ethyl esters led to a 17-fold increase in liver EPA and 
41-fold increase in epididymal fat pad EPA compared to CO.  The authors also 
found that feeding 91% of total fatty acids as DHA ethyl esters led to a 3-fold 
increase in liver DHA and 11-fold increase in epididymal fat pad DHA compared 
to corn oil.  In the current study, the AA, EPA, and DHA from KO individually 
contributed to less than 0.01% of total fatty acids were still capable of increasing 
tissue ω-3 LCPUFAs and lowering liver and adipose ω-6 long chain PUFAs 
concentrations.  This is important because it shows low dose ω-3 LCPUFAs in PL 
form produce similar effects to supplements providing high doses. 
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Reduction in tissue content of AA has been suggested for health benefits 
because higher AA concentration provides increased substrates for formation of 
pro-inflammatory eicosanoids such as PGE2 and TXA2 in response to cellular 
injury.  Based on the current study, feeding the KO + CO diet reduced urinary 
metabolites of PGE2 and TXA2.  This is consistent with previous studies showing 
that supplementation of either EPA or DHA decreases AA pro-inflammatory 
eicosanoid production.  Kelley et al. (1999) found that supplementation of 6 g/d 
DHA in healthy human subjects decreased serum PGE2 by 60-75% compared to 
the control diet.  The current study suggests that an EPA level of 0.01% and DHA 
level of 0.01% of the total diet has the ability to decrease PGE2 metabolites and 
TXA2 metabolites when compared to rats fed CO.  In the current study, it is 
possible that a difference in metabolism and tissue incorporation associated with 
fatty acids in the PL form may be partially responsible for the large reduction seen 
even with the low dietary contribution of EPA and DHA. 
EPA and DHA are highly susceptible to lipid peroxidation due to their 
high degree of unsaturation.  In our study, the increased tissue incorporation of 
EPA and DHA in rats fed KO + CO did not increase tissue or urinary TBARS.  
The lack of effect on oxidative stress seen in the current study may then be due to 
either a smaller dietary amount of EPA and DHA or difference in physiochemical 
form used.  In support, Song et al. (2001) observed increased levels of DHA in 
membrane phospholipids did not increase lipid peroxidation when DHA was 
provided in the PL form.  Based on these results, the ω-3 PUFA content of KPC 
does not contribute significantly to oxidative stress. 
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6.2 Conclusions 
A source of ω-3 PUFAs that provides high tissue accretion with the least 
lipid oxidation favors maximal health benefits.  The ω-3 PUFAs associated with 
KPC increased tissue incorporation without changing oxidative stability.  The 
0.9% KO provided by KPC was able to decrease AA tissue accretion and pro-
inflammatory eicosanoid metabolites.  The results suggest that consumption of 
KPC provides a healthy and sustainable alternative to fish or fish oil supplement.
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Table 1.  Diet Composition a (Gigliotti et al., 2008) 
  
Ingredients (g/kg diet) COb KO + COb 
Casein 115 0 
DL-Methionine 1.5 0 
Sucrose 531.8 609.8 
Corn Starch 200 229.4 
Corn Oil 53.5 49.9 
Cellulose 52 59.6 
Vitamin Mixa 10 11.5 
Ethoxyquin 0.01 0.01 
Mineral Mixa 13.4 15.3 
Calcium Phosphate 20.2 20.9 
Calcium Carbonate 2.6 3.6 
 
a Based on the AIN-93G diet vitamin and mineral mixes (Reeves et al., 1993). 
b Diet formulated for 872g of diet + 128g addition of KPC  
KPC = Krill Protein Concentrate
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Table 2.  Fatty Acid Composition of Dietary Oils 
 
Fatty acid KO + CO1 CO1 
 
18:2 (ω-6), LA 2.61 3.11 
18:3 (ω-3), ALA  0.05  0.05  
20:4 (ω-6), AA 0.01 -- 
20:5 (ω-3), EPA 0.11 -- 
22:6 (ω-3), DHA 0.11 -- 
ω-6: ω-3 10:1 62:1 
 
                     1Results are given as mg/g diet 
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Table 3.  Apparent Digestibility a 
 
  
 
Intake (mg) Fecal Excretion (mg) Apparent Digestibility (%) 
 
Fatty Acid KO + CO CO KO + CO CO KO + CO CO 
LA (18:2ω-6) 303.13±6.17* 346.50±13.79 17.34±3.66 10.68±2.54 93.76±1.06* 96.93±1.06 
ALA (18:3ω-3) 6.32±0.13* 5.49±0.22 2.88±0.65 2.07±0.41 49.02±10.58 62.86±6.26 
AA (20:4ω-6) 1.27±0.03* -- 0.97±0.20* -- 22.75±6.45* -- 
EPA (20:5ω-3) 13.28±0.27* -- 3.6±0.57 -- 70.12±3.52* -- 
DHA (22:6ω-3) 12.89±0.29* -- 0.77±0.21 -- 93.42±1.64* -- 
Total lipids (g) 6.16±0.13 5.91±0.24 0.78±0.11 0.76±0.10 86.10±1.36 87.17±1.36 
 
a Values are given as mean ± SEM 
* Indicates significant difference at P < 0.05 by the Student’s t-test 
LA = linolenic acid, ALA = α-linolenic acid, AA = arachidonic acid, EPA = eicosapentaenoic acid, DHA = Docosahexaenoic acid.  
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Table 4.  Fatty Acid Analysis of Tissues a 
 
  
 
Brain Gonadal Fat Pad Retroperitoneal Fat Pad Liver 
 
Fatty Acid           
(mg/g tissue) 
 
KO + CO CO KO + CO CO KO + CO CO KO + CO CO 
LA (18:2ω-6) 0.20 ±0.06  0.08±0.041  58.06 ±6.25 60.79±3.74 38.25 ±3.25 43.51±4.12 3.38 ±0.29 3.24±0.25 
ALA (18:3ω-3) 0.15±0.06 0.21±0.07 1.54 ±0.15 1.67±0.13 1.38±0.12 0.99±0.15 ND ND 
AA (20:4ω-6) 1.99±0.16  2.09±0.28  0.69±0.11 1.04±0.12 0.32±0.12* 0.90±0.09 1.94±0.10* 3.94±0.15 
EPA (20:5ω-3) ND ND 0.87±0.26* ND 0.74±0.19* ND 0.76±0.04* ND 
DHA (22:6ω-3) 2.85±0.24*  2.46±0.37  0.92±0.36* ND 0.78±0.19* ND 1.67±0.10* 0.72±0.026 
 
a Values are given as mean ± SEM 
* Indicates significant difference at P < 0.05 by the Student’s t-test 
ND = not detectable, LA = linolenic acid, ALA = α-linolenic acid, AA = arachidonic acid, EPA = eicosapentaenoic acid, DHA = 
Docosahexaenoic acid.  
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Table 5.  Oxidants and Antioxidants a 
 
 
 
KO + CO C+CO 
 
Antioxidant Capacity (mM trolox)  
Baseline Urine 3.58±0.71 5.09±0.62 
Final Urine 5.15±0.57 5.73±1.15 
TBARS (uM MDA)   
Baseline Urine 26.9 ± 4.9 29.8 ± 6.7 
Final Urine 8.4 ± 2.1 15.4 ± 4.5 
Retroperitoneal Fat Pad 2.30±0.21 2.20±0.23 
Gonadal Fat Pad 1.14±0.25* 2.00±0.15 
Liver 13.40±0.48 13.07±0.76 
Brain 5.57±0.28 5.93±0.38 
 
a Values are given as mean ± SEM 
* Indicates significant difference at P < 0.05 by the Student’s t-test 
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Figure 2.  Effect of diets on PGE2 metabolites a 
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a Values are given as mean ± SEM 
* Indicates significant difference at P < 0.05 by the Student’s t-test 
*
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Figure 3.  Effect of diets on 11-dehydro TXB2 a 
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a Values are given as mean ± SEM 
 
P = 0.054
